Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Imvotamab (IGM-2323) as a Single Agent and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas
Conditions
Interventions
imvotamab
Locations
26
United States
City of Hope
Duarte, California, United States
Moffitt Cancer Center
Tampa, Florida, United States
Norton Cancer Institute
Louisville, Kentucky, United States
Dana Farber Cancer Institute (DFCI)
Boston, Massachusetts, United States
NYU
New York, New York, United States
MSKCC
New York, New York, United States
Start Date
September 30, 2019
Primary Completion Date
February 16, 2024
Completion Date
February 22, 2024
Last Updated
July 24, 2024
NCT07545603
NCT06090539
NCT07523555
NCT07260812
NCT06337318
NCT05139017
Lead Sponsor
IGM Biosciences, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions